Clinical Trial Update: BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a BCMA-GPRC5D-targeted CAR-T therapy in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA/GPRC5D CAR-T therapy (BCMA/GPRC5D CAR-T cells)

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: RECRUITING